Geron startet durch! - 500 Beiträge pro Seite

[Waldorfde]

Steigt an der Nasdaq unter hohen Umsätzen aufgrund der nachfolgenden Meldung auf knapp 16$

Geron Reports Issuance of Second U.S. Patent for Human Embryonic Germ Cells


Business Wire via COMTEX

Jun 12, 2001 5:00:00 PM

MENLO PARK, Calif., Jun 12, 2001 (BW HealthWire) -- Geron Corporation (Nasdaq:GERN) announced today that the U.S. Patent Office has issued U.S. Patent No. 6,245,566, with claims directed to human embryonic germ cells. The patent is licensed exclusively to Geron from Johns Hopkins University.

Geron funded the work of Dr. John Gearhart at Johns Hopkins that led to the successful isolation of human embryonic germ (hEG) cells. These hEG cells are pluripotent, meaning that they are capable of developing into all cell types in the human body. The hEG cells are now being developed at Johns Hopkins with Geron funding for a variety of therapeutic and research applications.

`This is the second U.S. patent to issue in our hEG cell patent portfolio,` noted David J. Earp, J.D., Ph.D., Geron`s vice president of intellectual property. `The first, U.S. Patent No. 6,090,622, issued on July 18, 2000. Between them, the claims of these two patents cover methods of producing hEG cells, as well as the cells themselves. These two patents add to our existing portfolio of pluripotent stem cell intellectual property rights which includes two other issued U.S. patents covering human embryonic stem (hES) cells which were isolated by Dr. James Thomson at the University of Wisconsin using Geron funding. Our current portfolio of pluripotent stem cell intellectual property also includes over 50 patent applications pending around the world covering many aspects of cell growth, scale-up and differentiation into various clinically relevant cell types.`

`The research that we are now funding in Dr. Gearhart`s laboratory is focused on transplanting functional cells derived from the hEG cells into animal models of disease in order to restore tissue function,` stated Thomas Okarma, Ph.D., M.D., Geron`s president and chief executive officer. `At Geron, we are developing scalable methods for growing undifferentiated hES cells and have produced populations of several differentiated cell types such as hepatocytes, cardiomyocytes, and a number of neural cell types, including dopaminergic neurons. Our technical progress combined with our intellectual property assets surrounding these cells place Geron in a unique position to develop and commercialize therapeutic and research products based on these cells.`

Several disease conditions may be amenable to treatment with cells that are manufactured from hES or hEG cells, including Parkinson`s disease, diabetes, spinal cord injuries, liver disease and heart disease. Geron`s regenerative medicine unit is developing such cell-based therapies for these and other chronic diseases, as well as gene therapies based on Geron`s proprietary telomerase technology.

Geron`s research and development technologies unit is focused on producing human cells for large scale screening of drug candidates for drug discovery as well as toxicity and metabolism analyses. Cells such as hepatocytes, cardiomyocytes and neural cells that Geron would manufacture from hES or hEG cells could be produced in large, uniform lot sizes for use by pharmaceutical companies as a drug discovery platform.

Geron is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, and research tools for drug discovery. Geron`s product development programs are based upon three patented core technologies: telomerase, human embryonic stem cells and nuclear transfer.

This news release may contain forward-looking statements made pursuant to the `safe harbor` provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding product development and future applications of Geron`s technology constitute forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, dependence upon collaborative partners and the maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron`s periodic reports, including the quarterly report on Form 10-Q for the quarter ended March 31, 2001.

To receive an index and copies of recent press releases, call Geron`s News on Demand toll-free fax service, 800/782-3279. Additional information about Geron Corporation can be obtained at Website://www.geron.com.



CONTACT:          Geron Corporation                                      David Greenwood, 650/473-7765                          or                                              Burns McClellan                                             Nancy Robinson, 415/352-6262 (Investors) URL:               Website://www.businesswire.com Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2001 Business Wire.  All rights reserved.   

[Forum]

Die waren schon immer ein Kauf !

[basko1]

I bin anfange am WO.
Wie kann ich ein neu Thema anlegen.
Danke